BeiGene falls on immune events for B cell cancer combo

BeiGene Ltd. (NASDAQ:BGNE) lost $4.59 to $91.39 Monday after reporting three immune-related events in a Phase Ib trial of zanubrutinib (BGB-3111) plus tislelizumab (BGB-A317) to treat B cell malignancies

Read the full 296 word article

User Sign In